Avalo Therapeutics, Inc.
AVTX· Nasdaq
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q3 2015 | Q3 2014 |
|---|---|---|
| Net Income | -$692.00K | -$5.84M |
| EPS Diluted | -$1.06 | $10.35 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR